Abstract
Medications to treat pain are in widespread use and any change in the risk of fracture may consequently have a significant impact at a population level. Strong analgesics of the opiate and opiate-like group are associated with an increased risk of fractures probably from an increased risk of falls resulting from the dizziness induced by these drugs. However, not all strong analgesics are associated with an increased risk of fractures. The differences are not readily explained from variations in pharmacokinetic properties. Weak analgesics mainly interact with the prostaglandin system; these drugs include non-steroidal anti-inflammatory drugs (NSAIDs), acetylsalicylic acid and acetaminophen. Acetaminophen is associated with an increased risk of fractures while acetylsalicylic acid is not. Some but not all NSAIDs are associated with an increased fracture risk, and the differences are not explained by variations in pharmacokinetic properties. More research is needed to determine if some analgesics are safer than others with respect to fracture risk.
Keywords: Pain-Relief Medication, Fractures, analgesics, opiate, prostaglandin system, non-steroidal anti-inflammatory drugs (NSAIDs), acetylsalicylic acid, acetaminophen
Current Drug Safety
Title: Pain-Relief Medication and Risk of Fractures
Volume: 3 Issue: 3
Author(s): Peter Vestergaard
Affiliation:
Keywords: Pain-Relief Medication, Fractures, analgesics, opiate, prostaglandin system, non-steroidal anti-inflammatory drugs (NSAIDs), acetylsalicylic acid, acetaminophen
Abstract: Medications to treat pain are in widespread use and any change in the risk of fracture may consequently have a significant impact at a population level. Strong analgesics of the opiate and opiate-like group are associated with an increased risk of fractures probably from an increased risk of falls resulting from the dizziness induced by these drugs. However, not all strong analgesics are associated with an increased risk of fractures. The differences are not readily explained from variations in pharmacokinetic properties. Weak analgesics mainly interact with the prostaglandin system; these drugs include non-steroidal anti-inflammatory drugs (NSAIDs), acetylsalicylic acid and acetaminophen. Acetaminophen is associated with an increased risk of fractures while acetylsalicylic acid is not. Some but not all NSAIDs are associated with an increased fracture risk, and the differences are not explained by variations in pharmacokinetic properties. More research is needed to determine if some analgesics are safer than others with respect to fracture risk.
Export Options
About this article
Cite this article as:
Vestergaard Peter, Pain-Relief Medication and Risk of Fractures, Current Drug Safety 2008; 3 (3) . https://dx.doi.org/10.2174/157488608785699504
DOI https://dx.doi.org/10.2174/157488608785699504 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Exercise Induced Cardioprotection: An Overview of a Unique Form of Preconditioning
Current Cardiology Reviews Dysregulation of SIRT-1 Signaling in Multiple Sclerosis and Neuroimmune Disorders: A Systematic Review of SIRTUIN Activators as Potential Immunomodulators and their Influences on other Dysfunctions
Endocrine, Metabolic & Immune Disorders - Drug Targets The Brain, the Penis and Steroid Hormones: Clinical Correlates with Endothelial Dysfunction
Current Pharmaceutical Design Female Sexual Dysfunction: Therapeutic Options and Experimental Challenges
Cardiovascular & Hematological Agents in Medicinal Chemistry Natural Compounds and Drug Discovery: Can Cnidarian Venom Play a Role?
Central Nervous System Agents in Medicinal Chemistry Highest Mortality During the Last Year Before and the First Year After Start of Dialysis Treatment in Type 2 Diabetic Patients with Nephropathy
Current Diabetes Reviews Thrombolytic Therapy in Acute Ischemic Stroke - Basic Concepts
Current Vascular Pharmacology Bivalirudin or Heparin Treatment During Transcatheter Valve Interventions: Where are we Now?
Current Pharmaceutical Design Combination of a Sterol Absorption Inhibitor and Cardiovascular Agents for the Treatment of Dyslipidemia
Recent Patents on Cardiovascular Drug Discovery Bone Disease - Current Knowledge and Future Prospects
Current Genomics Inducers of Heme Oxygenase-1
Current Pharmaceutical Design Directed Differentiation of Pluripotent Cells Towards Therapeutic Stem Cells
Recent Patents on Regenerative Medicine Biomarkers Linking PCB Exposure and Obesity
Current Pharmaceutical Biotechnology Vitamin D and Infectious Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Strategies to Tackle Early Low Flow States in the Extremely Preterm Infant
Current Pediatric Reviews Myocardial Infarction Following Atherosclerosis in Murine Models
Current Drug Targets Biologics and the Cardiovascular System: A Double-Edged Sword
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Mst1: Function and Mechanism in Brain and Myocardial Ischemia Reperfusion Injury
Current Neuropharmacology Application of Metabolomics in Drug Discovery, Development and Theranostics
Current Metabolomics New Concept of Vascular Calcification and Metabolism
Current Vascular Pharmacology